US 11,959,924 B2
Methods for performing ex vivo diagnostic tests for the presence of a proliferation-inducing ligand (APRIL) in a sample
Hans Van Eenennaam, Nijmegen (NL); Andrea Van Elsas, Oss (NL); Lilian Driessen, Baarlo (NL); and Jan Paul Medema, Amsterdam (NL)
Assigned to ADURO BIOTECH HOLDINGS, EUROPE B.V., Rosmalen (NL)
Filed by ADURO BIOTECH HOLDINGS, EUROPE B.V., Oss (NL)
Filed on Jun. 28, 2021, as Appl. No. 17/360,719.
Application 17/360,719 is a continuation of application No. 16/128,416, filed on Sep. 11, 2018, granted, now 11,047,864.
Application 16/128,416 is a continuation of application No. 14/916,962, granted, now 10,107,821, issued on Oct. 23, 2018, previously published as PCT/NL2014/050612, filed on Sep. 5, 2014.
Claims priority of application No. 2011406 (NL), filed on Sep. 6, 2013.
Prior Publication US 2021/0325404 A1, Oct. 21, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/68 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01)
CPC G01N 33/6854 (2013.01) [C07K 16/241 (2013.01); C07K 16/2875 (2013.01); G01N 33/6863 (2013.01); C07K 2317/565 (2013.01); G01N 2333/525 (2013.01)] 23 Claims
 
1. A method for performing an ex vivo diagnostic test for the presence of A Proliferation-Inducing Ligand (APRIL) in a sample, comprising:
a) contacting the sample with an APRIL-binding antibody comprising:
i) a VH domain comprising an amino acid sequence having complementarity determining region (CDR) sequences set forth in SEQ ID NOs: 25-27, and a VL domain comprising an amino acid sequence comprising CDR sequences set forth in SEQ ID NOs: 28-30,
ii) a VH domain comprising an amino acid sequence having complementarity determining region (CDR) sequences set forth in SEQ ID NOs: 5-7 and a VL domain comprising an amino acid sequence comprising CDR sequences set forth in SEQ ID NOs: 8-10,
iii) a VH domain comprising an amino acid sequence having complementarity determining region (CDR) sequences set forth in SEQ ID NOs: 15-17 and a VL domain comprising an amino acid sequence comprising CDR sequences set forth in SEQ ID NOs: 18-20,
iv) a VH domain comprising an amino acid sequence having complementarity determining region (CDR) sequences set forth in SEQ ID NOs: 35-37 and a VL domain comprising an amino acid sequence comprising CDR sequences set forth in SEQ ID NOs: 38-40, or
v) a VH domain comprising an amino acid sequence having complementarity determining region (CDR) sequences set forth in SEQ ID NOs: 45-47 and a VL domain comprising an amino acid sequence comprising CDR sequences set forth in SEQ ID NOs: 48-50; and
b) detecting binding between APRIL in the human sample and the APRIL-binding antibody.